scholarly journals Bilateral Lung Transplantation for End-Stage Respiratory Failure from COVID-19 Pneumonia

2021 ◽  
Vol 40 (4) ◽  
pp. S500
Author(s):  
N. Maniar ◽  
J. Coster ◽  
G. Li ◽  
J. Segraves ◽  
M. Hemmersbach-Miller ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Lung Transplantation ◽  
Bilateral Lung Transplantation ◽  
Bilateral Lung ◽  
End Stage

Lung transplantation for silicosis and recovery: an Australian case study

2021 ◽  
Vol 30 (3) ◽  
pp. 178-183
Author(s):  
Kate McEwen ◽  
Lyndell Brodie
Keyword(s):  
Lung Transplantation ◽  
Medication Management ◽  
Social Situation ◽  
Bilateral Lung Transplantation ◽  
Transplantation Surgery ◽  
Australian Case ◽  
Bilateral Lung ◽  
End Stage

Lung transplantation is a well-established treatment for a variety of end-stage pulmonary diseases. However, the journey of a lung transplant recipient is complex and multifaceted. Silicosis is a rare indication for lung transplantation, but no other treatment is yet available for this disease in its end stages. This Australian case study presents a 52-year-old man with silicosis who received bilateral lung transplantation. The patient was frequently noncompliant with noninvasive ventilation therapy and experienced the complication of type 2 respiratory failure. Patient education and support provided, particularly around medication management following transplantation surgery, are discussed here. The patient's social situation and its implications for both him and his family are also considered.

Bilateral Lung Transplantation for Castleman Disease with End‐stage Bronchiolitis Obliterans

2021 ◽  
Author(s):  
Bingqing Yue ◽  
Jian Huang ◽  
Lei Jing ◽  
Huaqing Yu ◽  
Dong Wei ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Bronchiolitis Obliterans ◽  
Castleman Disease ◽  
Bilateral Lung Transplantation ◽  
Bilateral Lung ◽  
End Stage

scholarly journals Pulmonary Pathology of COVID-19 Following 8 Weeks to 4 Months of Severe Disease: A Report of Three Cases, Including One With Bilateral Lung Transplantation

2020 ◽  
Author(s):  
Scott W Aesif ◽  
Alejandro C Bribriesco ◽  
Ruchi Yadav ◽  
Summer L Nugent ◽  
Dmitriy Zubkus ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Acute Respiratory Failure ◽  
Lung Transplantation ◽  
Interstitial Fibrosis ◽  
Severe Disease ◽  
Disease Onset ◽  
Lung Pathology ◽  
Bilateral Lung Transplantation ◽  
Pulmonary Pathology ◽  
Bilateral Lung

Abstract Objectives Current knowledge of the pulmonary pathology of coronavirus disease 2019 (COVID-19) is based largely on postmortem studies. In most, the interval between disease onset and death is relatively short (<1 month). Information regarding lung pathology in patients who survive for longer periods is scant. We describe the pathology in three patients with severe COVID-19 who underwent antemortem examination of lung tissue at least 8 weeks after initial diagnosis. Methods We conducted a retrospective case series. Results The first patient developed acute respiratory failure and was started on extracorporeal membrane oxygenation (ECMO) on day 21, with subsequent hemothorax. Debridement (day 38) showed extensive lung infarction with diffuse alveolar damage and Candida overgrowth. The second patient developed acute respiratory failure requiring mechanical ventilation that did not improve despite ECMO. Surgical lung biopsy on day 74 showed diffuse interstitial fibrosis with focal microscopic honeycomb change. The third patient also required ECMO and underwent bilateral lung transplantation on day 126. The explanted lungs showed diffuse interstitial fibrosis with focal microscopic honeycomb change. Conclusions This series provides histologic confirmation that complications of COVID-19 after 8 weeks to 4 months of severe disease include lung infarction and diffuse interstitial fibrosis.

scholarly journals Relapse of Lymphangioleiomyomatosis Five Years after Bilateral-Lung Transplantation

2021 ◽  
Vol 24 (9) ◽  
pp. 701-703
Author(s):  
Jalal Heshmatnia ◽  
Maryam Sadat Mirenayat ◽  
Mitrasadat Rezaei ◽  
Felix Bongomin ◽  
Mehrdad Bakhshayeshkaram ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Viable Option ◽  
Bilateral Lung Transplantation ◽  
Pulmonary Lymphangioleiomyomatosis ◽  
Progressive Dyspnea ◽  
Stage Disease ◽  
Uncommon Disease ◽  
Progressive Respiratory Failure ◽  
Bilateral Lung ◽  
End Stage

Pulmonary lymphangioleiomyomatosis (LAM) is an uncommon disease principally affecting women during childbearing years and eventually leading to progressive respiratory failure. Lung transplantation is a viable option for patients with end-stage disease. LAM-related complications remain common, but recurrence of LAM following allograft transplantation is rare. We present a 25-year-old woman who presented with progressive dyspnea five years after bilateral lung transplantation for end-stage LAM. Histological examination of transbronchial lung biopsy sample confirmed recurrent LAM. We changed cyclosporine to sirolimus and she is currently being considered for re-transplantation.

Long-Term Results of Bilateral Lung Transplantation in Patients With End-Stage Pulmonary Lymphangioleiomyomatosis

2019 ◽  
Vol 29 (2) ◽  
pp. 115-121 ◽  
Author(s):  
Jawad Salman ◽  
Fabio Ius ◽  
Wiebke Sommer ◽  
Thierry Siemeni ◽  
Felix Fleissner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Transplantation ◽  
Short Form ◽  
Self Report ◽  
Long Term Results ◽  
Actuarial Survival ◽  
Bilateral Lung Transplantation ◽  
Bilateral Lung ◽  
End Stage

Introduction: Lymphangioleiomyomatosis (LAM) is a rare disease in women, leading to progressive deterioration of lung function and respiratory failure. We describe the outcome of patients with end-stage LAM who underwent lung transplantation at our center. Materials and Methods: The records of patients with LAM transplanted at our institution between February 1997 and May 2015 were reviewed retrospectively. Morbidity and mortality were analyzed, and actuarial survival was calculated using Kaplan-Meier methods. The cumulative survival of transplant patients with LAM at our center was compared with survival after transplantation due to different diseases at our center and the results of the International Society for Heart and Lung Transplantation. Quality of life was assessed by a patient self-report at the end of the first postoperative year. Results: During the study period, 25 patients underwent lung transplantation for LAM. All patients were women with a mean age of 50 (9) years. Thirteen patients (52%) had undergone previous thoracotomy. All patients (100%) received bilateral lung transplantation. One (4%) case of in-hospital mortality occurred and 9 (36%) late deaths. Two (8%) cases of late death were due to chronic lung allograft dysfunction. The 1-, 3-, and 5-year survival rates were 92%, 84%, and 76%, respectively. Quality-of-life ratings were above the normal in all eight 36-Item Short Form Health Survey subscales 1 year after transplantation. Conclusions: Lung transplantation offers a valuable therapy for patients with end-stage pulmonary LAM.

Sign in / Sign up

Export Citation Format

Share Document